About Gwo Xi

Gwo Xi Stem Cell Applied was founded in Taiwan in 2004. It has focused on the research and application of stem cell technology to support stem cell health and treat diseases with unmet of under-served medical needs.

Gwo Xi office website

Gwo Xi Vision

Gwo Xi endeavors to be a global leader in the field of regenerative medicine.

Gwo Xi Mission

Gwo Xi devotes to the development of stem cell technology to maintain stem cell healthy and apply in the field of regenerative medicine.

Gwo Xi Business Operation

1. Stem Cell Drug

TFDA approved the phase I clinical trial of Stem-Cell Drug for Liver Cirrhosis-GXHPC1 and Stem-Cell Drug for Stroke-GXNPC1 on November 2015 and June 2016. Stem-Cell Drug GXHPC1 is for the treatment of liver cirrhosis and fibrosis and GXNPC1 is for the treatment of stroke. One of clinical trials: “Clinical Trial Study About Human Adipose-Derived Stem Cells in the Liver Cirrhosis” has already received all patients. Gwo Xi develop the research and application of stem cell technology to support stem cell health and treat disease with unmet of under-served medial needs at the same time.

2. Quality Testing Services of Cellular Products

Gwo Xi- GTesting Testing Laboratory launched “Quality Testing Services of Cellular Products”, providing testing services of cell therapy. GTesting will provide the certification report according to the “TFDA Guidance on Investigational Cell Therapy Products” and help our customers monitor quality of cellular products, and then concentrate the development of cell therapy products, accelerate the stem cell new drug on the market. GTesting will protect the confidentiality of all customers’ information to meet the needs of customers.

3. Stem Cell OEM/ODM Services

GwoXi “The production technology platform of pharmaceutical-grade adipose-derived stem cell products (Hereinafter referred to as “the platform”)” has been established isolation, purification, expansion and storage of human stem cells of process patents. All process of the platform is compliance with “TFDA Guidance on Investigational Cell Therapy Products” and Good Tissue Practice (GTP) requirements. The platform provides stem cell technology related services of expertise, technology, testing laboratory and original equipment manufacturer (OEM). TFDA approved the phase I clinical trial of Stem-Cell Drug for Liver Cirrhosis-GXHPC1 and Stem-Cell Drug for Stroke-GXNPC1 on November 2015 and June 2016. All of the above confirmed that our company has expertise of human stem cell products and future development potential.

4. Stem Cell Storage Services

GwoXi “Stem Cell Storage Services” has been established isolation, purification, expansion and storage of human stem cells of process patents. Animal experiments confirmed that it is no tumorigenicity and no chromosomal abnormality of stem cell products. All process of the subject of application is compliance with GTP requirements.